赛隆药业集团股份有限公司关于控股股东、实际控制人协议转让股份过户完成暨公司控制权发生变更的公告

Core Viewpoint - The announcement details the completion of the transfer of 14.16% of the shares of Sairong Pharmaceutical Group Co., Ltd. from its former controlling shareholders to Hainan Yayi, resulting in a change of control of the company [1][2][3]. Group 1: Share Transfer Details - The share transfer involved 24,912,205 shares at a price of 8 RMB per share, totaling 199,297,640 RMB [2][4]. - Following the transfer, Hainan Yayi will hold 24.60% of the voting rights in the company, establishing it as the new controlling shareholder [3][6]. Group 2: Control Changes - After the transfer, the former controlling shareholders, Cai Nanguai and Tang Lin, will hold 42.46% of the shares but will relinquish all voting rights except for the rights to dividends and share disposal [2][6]. - The company will now be classified as having no actual controller since Hainan Yayi currently has no actual controlling party [3][6]. Group 3: Compliance and Commitments - Hainan Yayi has committed not to transfer or delegate management of its shares for 18 months following the completion of the transfer [8]. - The share transfer complies with relevant laws and regulations, ensuring no adverse effects on the company's operations or minority shareholders [8].